Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?

Transfusion and Apheresis Science

Volumn 39, Issue 1, 2008, Pages 69-74

  Hellstern, Peter ^a  

^a Academic City Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BLOOD CLOTTING FACTOR; FIBRINOGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; OCTAPLAS; PLASMA PROTEIN; UNIPLAS;

APHERESIS; ARTICLE; BLOOD TRANSFUSION REACTION; FREEZE DRYING; HUMAN; LUNG INJURY; LYOPHILISATE; PHOTOOXIDATION; PLASMA TRANSFUSION; ULTRAVIOLET RADIATION;

ABO BLOOD-GROUP SYSTEM; BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; DISINFECTION; FREEZE DRYING; HUMANS; PLASMA;

EID: 47349103797     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.05.005     Document Type: Article

References (32)

1. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apheresis Sci 35 (2006) 83-90
2. Seghatchian J., and de Sousa G. Pathogen reduction system for blood components: the current position and future trends. Transfus Apheresis Sci 35 (2006) 189-196
3. Runkel S., Haubelt H., Hitzler W., and Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 45 (2005) 427-432
4. Seghatchian J., and Krailadsiri P. The quality of methylene blue light treated FFP and cryoprecipitate. Transfus Apheresis Sci 25 (2001) 227-231
5. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion 43 (2003) 1322-1329
6. Singh Y., Sawyer L.S., Pinkoski L.S., Dupuis K.W., Hsu J.C., Lin L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46 (2006) 1168-1177
7. Goodrich R.P., Edich R.A., Li J., and Seghatchian J. The Mirasol PT system for pathogen reduction pf platelet and plasma. Transfus Apheresis Sci 35 (2006) 5-17
8. Stanworth S.J., Brunskill S.J., Hyde C.J., McLelland D.B.L., and Murphy M.F. Is fresh frozen plasma clinically effective? A systematic review of randomized trials. Brit J Haematol 126 (2004) 139-152
9. Duguid J., ÓShaughnessy D.F., Atterbury C., Bolton Maggs P., Murphy M., Thomas D., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Brit J Haematol 126 (2004) 11-28
10. De la Rubia J., Arriaga F., Linares D., Larrea L., Caprio N., Marty M.L., et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Brit J Haematol 114 (2001) 721-723
11. Alvarez-Larrán A., Del Rio J., Ramirez C., Albo C., Peňa F., Campos A., et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
12. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
13. Cardigan R., Allford S., and Williamson L. Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 117 (2002) 253-254
14. Atance R., Pereira A., and Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
15. De Alarcon P., Benjamin R., Dugdale M., Kessler C., Shopnik R., Smith P., et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 45 (2005) 1362-1372
16. Mintz P.D., Neff A., MacKenzie M., Goodnough L.T., Hillyer C., Kessler C., et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46 (2006) 1693-1704
17. Mast A.E., Stadanlick J.E., Lockett J.M., and Dietzen D.J. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 94 (1999) 3922-3927
18. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
19. Beeck H., and Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74 Suppl. 1 (1998) 219-223
20. Haubelt H., Blome M., Kiessling A.H., Isgro F., Bach J., Saggau W., et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 82 (2002) 9-14
21. Solheim B.G., and Hellstern P. Composition, efficacy, and safety od S/D-treated plasma. Transfusion 43 (2003) 1176-1178
22. Salge-Bartels U., Breitner-Ruddock S., Hunfeld A., Seitz R., and Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?. Transfus Med 16 (2006) 266-275
23. Hellstern P., Sachse H., Schwinn H., and Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63 (1992) 178-185
24. Hellstern P., and Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 107 (2002) S3-S8
25. Chekrizova V., and Murphy W.G. Solvent-detergent plasma: use in neonatal patients, in adult and pediatric patients with liver disease and in obstetric and gynecological emergencies. Transfus Med 16 (2006) 85-91
26. Santagostino E., Mancuso M.E., Morfini M., Schianovi M., Tagliaferri A., Giovanni B., et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 91 (2006) 634-639
27. Österreichisches Hämovigilanz-Register; 2004, www.bmfg.gv.at.
28. McCarthy L.J. The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Brit J Haematol 133 (2006) 107
29. Tølløfsrud S., Noddeland H., Svennevig J.L., Bentsen G., Mollnes T.E., and Solheim B.G. Universal fresh frozen plasma (Uniplas): a safe product on open-heart surgery. Intensive Care Med 29 (2003) 1736-1743
30. Solheim B.G., Granov D.A., Juralv V.A., Krawczyk M., Kubishkin V.A., Patutko U.I., et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 89 (2005) 19-26
31. Riedler G.F., Haycox A.R., Duggan A.K., and Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85 (2003) 88-95
32. Sachs U.J., Kauschat D., and Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 45 (2005) 1628-1631